Catheter-based renal denervation for treatment of hypertension

The Lancet

Volumn 390, Issue 10108, 2017, Pages 2124-2126

  Azizi, Michel ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; HUMAN; HYPERTENSION; KIDNEY ARTERY; KIDNEY DENERVATION; NOTE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AUTONOMIC DENERVATION; BLOOD PRESSURE MEASUREMENT; CATHETER ABLATION; COMPARATIVE STUDY; FEMALE; FOLLOW UP; INNERVATION; KIDNEY; MALE; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ANTIHYPERTENSIVE AGENTS; AUTONOMIC DENERVATION; BLOOD PRESSURE DETERMINATION; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85028401021     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32293-6     Document Type: Note

References (12)

1. Bhatt, DL, Kandzari, DE, O'Neill, WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370 (2014), 1393–1401.
2. Persu, A, Kjeldsen, S, Staessen, JA, Azizi, M, Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep, 18, 2016, 6.
3. Azizi, M, Sapoval, M, Gosse, P, et al., for the Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385 (2015), 1957–1965.
4. Mahfoud, F, Bohm, M, Azizi, M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 36 (2015), 2219–2227.
5. White, WB, Turner, JR, Sica, DA, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension interactive forum held in Bethesda, MD, U.S.A, October 10th 2013. J Am Soc Hypertens 8 (2014), 743–757.
6. Mahfoud, F, Schmieder, RE, Azizi, M, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J, 2017 published online May 5. DOI:10.1093/eurheartj/ehx215.
7. Townsend, RR, Mahfoud, F, Kandzari, DE, et al., on behalf of the SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, 2017 published online Aug 28. http://dx.doi.org/10.1016/S0140-6736(17)32281-X.
8. Kandzari, DE, Kario, K, Mahfoud, F, et al. The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 171 (2016), 82–91.
9. Pocock, SJ, Clayton, TC, Stone, GW, Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 66 (2015), 2886–2898.
10. Poulter, NR, Prabhakaran, D, Caulfield, M, Hypertension. Lancet 386 (2015), 801–812.
11. Persu, A, Sapoval, M, Azizi, M, et al. Renal artery stenosis following renal denervation: a matter of concern. J Hypertens 32 (2014), 2101–2105.
12. Olsen, MH, Angell, SY, Asma, S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 388 (2016), 2665–2712.